Sou Hu Cai Jing·2026-01-14 11:59Core Viewpoint - Spring Medical (688236) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The net profit for Q3 was 77.06 million yuan, showing a staggering increase of 531.12% year-on-year [2]. - The non-recurring net profit for Q3 was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 14, 2026, Spring Medical's stock closed at 26.66 yuan, with an increase of 1.18% [1]. - The turnover rate was 1.95%, with a trading volume of 56,100 hands and a transaction amount of 154 million yuan [1]. - On January 14, the net inflow of main funds was 21.38 million yuan, accounting for 13.92% of the total transaction amount [1]. - Retail investors experienced a net outflow of 18.21 million yuan, representing 11.86% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 8 institutions have given buy ratings for Spring Medical, with a target average price of 31.7 yuan [3].